C-ZIMKAisa Therapeutics
anti-inflammatory, anti-senescence, nutraceuticals
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ZIMK
C-ZIMKC-ZIMKanti-inflammatory, anti-senescence, nutraceuticals
0-100 chain-logic scale · 15 dimensions · scored on public evidence
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
WO2009040420A2 - Use of a monoterpene to increase tissue repair - Google Patents WO2009040420A2 - Use of a monoterpene to increase tissue repair - Google Patents Use of a monoterpene to increase tissue repair Download PDF Info Publication number WO2009040420A2 WO2009040420A2 PCT/EP2008/062938 EP2008062938W WO2009040420A2 WO 2009040420 A2 WO2009040420 A2 WO 2009040420A2 EP 2008062938 W EP2008062938 W EP 2008062938W WO 2009040420 A2 WO2009040420 A2 WO 2009040420A2 Authority WO WIPO (PCT) Prior art keywords skin limonene monoterpene group use according Prior art date 2007-09-26 Legal status (The … is and makes no representation as to the accuracy of the status listed.) Ceased Application number PCT/EP2008/062938 Other languages English ( en ) French ( fr ) Other versions WO2009040420A3 ( en Inventor Patrizia D'alessio Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) AISA THERAPEUTICS Original Assignee AISA THERAPEUTICS Priority date (The prior … sted.) 2007-09-26 Filing date 2008-09-26 Publication date 2009-04-02 2008-09-26 Application filed by AISA THERAPEUTICS filed Critical AISA THERAPEUTICS 2008-09-26 Priority to ES08804813T priority Critical patent/ES2412485T3/es 2008-09-26 Priority to DK08804813.7T priority patent/DK2190424T3/da 2008-09-26 Priority to PL08804813T priority patent/PL2190424T3/pl 2008-09-26 Priority to BRPI0818189 priority patent/BRPI0818189A2/pt 2008-09-26 Priority to CA2700601A priority patent/C … or treating non-pathological conditions of skin or mucosa defects comprises the application of a cosmetic formulation comprising a monoterpene, in one dose or in repeated doses and at specified intervals of time, on said skin or mucosa defect. the administration regimen may be for instance for a period of more than 4 weeks, or more than 8 weeks. the range of dose of monoterpene may be between 0.1 mg/kg/day and 100 mg/kg/day. More preferably, the dose range is between 1 mg/kg/ … noterpene according to the invention is preferably carried out topically by the application of a cosmetic formulation on skin or a mucosa. Cosmetic formulations may include, besides a monoterpene, other active principles and one or more cosmetically acceptable carriers. cosmetically acceptable carriers means a carrier to be used in contact with t
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics: Anti-inflammatory and anti-senescence properties | AISA Therapeutics - Anti-Inflammatory Senescence Actives posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Li … or add a comment, sign in Olga Blaut 8mo Report this post 🏆 The 2025 The Nobel Prize in Medicine marks a turning point for the future of #healthcare — and for all of us in #pharmalogistics 💊📦❄️🚚✈️📍📈 🧬 As immune tolerance research moves from lab to clinic, our industry must evolve to deliver therapies 🎗️🧬 that are alive, precise, and personalized 😷 🚚💡 What does it mean for #pharma #supplychain ✈️❄️📍 of tomorrow ❓ The copy of videos 🎥 🎥 are on YouTube: https://ln
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
2018 ICAD Speakers - Past Conferences - ICAD 2023 Home About ISOAD Mission Bylaws Committees Officers Chapters Publication Journal Editorial Board Payment Partners Membership About Membership Membership Categories and Fees Join ISOAD Member Directory Donation Credit Card Check Conference Resolution Call for paper Conference Committee Deadline Registration Payment Submission Themes and Topics Confirmed Speakers Conference Program Accommodations Transportation Frequently Asked Questions Past Conferences Resources Contact us Conference Home >> Conference &nb … r of sixty articles in peer-reviewed international journals, holder of the PES (Award of Scientific Excellence) in mathematics in 2010 and physics in 2014, Jean-Marc Gambaudo is also an honorary professor at the university. from Chile. Pr. PATRICK BAQUE Prof. Anatomy & Surgeon Nice, France He is surgeon, Professor of Anatomy - General Surgery at the CHU in Nice, France. Doctor of medicine in 1998, he did most of his medical studies were at the Faculty … the European Academy of Sciences in 2010. In 2012, he won the Leopold Griffuel Prize from the French ARC Foundation for Cancer Research. Kroemer is the editor-in-chief of the journal Cell Death & Disease . Pr STEVEN ARTANDI, Keynote lecture Stanford University, California, USA Dr. Steven Artandi is a hematologist in Stanford, California and is affiliated with multiple hospitals in the area, including Stanford Health Care-Stanford Hospital and … face of further stress. Prof. Bjorn Schumacher has been awarded the Innovation Prize from the State of North Rhine-Westphalia, holds the ERC starting grant and coordinates the European training network “CodeAge” on chronic DNA damage responses in aging. Pr PATRIZIA ANNA D’ALESSIO AISA Therapeutics Award Innovative Entrepreneurship Ministry of Research France University Paris Sud-11 and Biopark Cancer Campus 1 mail Pr Georges Mathé … SA Therapeutics, following the French Ministry of Higher Education and Research Award for Innovative Enterprises. Since 2015, the AISA Moleculum trademark, resulting from 10 years of preclinical and clinical studies – including the European FP7 Ristomed project – offers a dietary and cosmeceutic supplement to relieve stress and inflam
AISA Therapeutics - Anti-Inflammatory Senescence Actives
#aisatherapeutics #senescence #inflammatory #antiinflammatory #science #aging #antiaging | AISA Therapeutics - Anti-Inflammatory Senescence Actives LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
NewsManager Company Coverage.xlsm - EvaluatePharma EN English Deutsch Français Español Português Italiano Român Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Türkçe Suomi Latvian Lithuanian český русский български العربية Unknown Login to YUMPU News Login to YUMPU Publishing TRY ADFREE Discover products News Publishing Magazines Create ePaper Login to YUMPU News Login to YUMPU Publishing × Attention! Your ePaper is waiting for publication! By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 mi
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
AISA Moleculum: Natural Anti-Aging and Anti-Inflammatory | AISA Therapeutics - Anti-Inflammatory Senescence Actives posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By c
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
#longevitysummitdublin #womenshealth #longevityscience #healthspan #futureofhealth #trinitycollegedublin #clinicalinnovation #biotech #agingresearch | Longevity Summit Dublin LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Rejec
Founders Longevity Forum Singapore – Founders Longevity Forum Skip to content About Speakers Agenda 2025 Gallery Content Hub Discover Singapore About Speakers Agenda 2025 Gallery Content Hub Discover Singapore Founders Longevity Forum Singapore: Unlock Healthy Longevity The global longevity event hosted in Asia Pacific. 2026 dates coming soon 2025 Agenda In partnership with About Founders Longevity Forum Singapore: Unlocking Healthy Longevity, produced by Founders Forum Group, Longevity.Technology and the National University of Singapore (NUS)’s Academy for Healthy Longevity Yong L … ent TruDiagnostic Emil Kendziorra Tomorrow Biostasis Petr Šrámek Longevity.tech fund Anna Erat Longevity.tech fund Greg MacPherson SRW Laboratories Kevin Slawin Eos SENOLYTIX, Inc Cuilin Zhang National University of singapore Yuta Lee Accelerated Biosciences Siobhan Mitchell MitoQ Elvin Siew Avio Health Luc Aguilar L'Oreal Luigi Fontana University of Sydney Jan Gruber National University of singapore & yale-nus college Frank pun insilico medicine Nicole Sirotin Institute … and Aging Research, University of Zurich) 4:30PM Rising Star Announcement & Award Presentation 4:40PM Closing Remarks – Andrea Maier (Co-Founder, NUS) 9:00am Entry and Welcome Remarks – Phil Newman 9:05am Reframing Healthspan as a Computer Science Problem – Peng Ong (Monk Hill Ventures/ Elyx.Life) 9:25am Aging Therapeutics: Advancing Global Healthspan – Brian Kennedy (Distinguished Professor of Biochemistry and Physiology, National University of Si … gevity Therapies – Petr Sramek (Managing Partner & VC, Longevity.Tech Fund), David Gobel (Founder, Methuselah Foundation), Boyang Wang (Immortal Dragons) 10:40am Morning Break, Coffee and Refreshments 11:10am Pitching Companies – Oleg Tetrin (Longevity InTime), Tim Mak (Trilliome), Boyang Wang (Immortal Dragons) 11:40am AI for Drug Discovery – Frank Pun (Head of Insilico Hong Kong, Insilico Medicine) 12:00pm Ageing Biotechnology: Targeted Reversal- Boris … mek serves as CEO of HealthyLongevity.clinic, Managing Partner of LongevityTech.fund, Co-founder of Longevityforum.eu and is a Board member of several biotech companies. Šrámek mentors longevity companies at Foresight Institute and Longevity Biotech Fellowship and helps innovative startups in Artificial Intelligence and Longevity technology grow
AISA Care | Complément alimentaire naturel anti âge Nos Produits Tous nos produits Explorez nos solutions anti-inflammatoires et bien-être Découvrir Gélules Ainti-inflammatoire AISA moleculum 120€ Best seller Routine AISA Découvrez la routine à mettre en oeuvre Top Action Science Sciences & Preuves Inflammation silencieuse Stress & cortisol Axe intestin, cerveau & peau Sénescence & inflammaging d-Limonène Conseils Approche Fondatrice Vision AISA Recherche & innovation Partenaires Aide Support & FAQ Livraison Retour & Remboursement Contact FR EN 0 Validé cliniquement
--> Patrizia d’Alessio Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal Animal … tified small non-toxic anti-inflammatory actives. 2005 French Ministry Research Award Innovative Enterprises. Founder of R&D start-up AISA Therapeutics. Three patents granted in Europe, USA, China. 2009 European FP7 Ristomed project. 2015 AISA Moleculum® trademark - a dietary supplement to relieve stress and signs of inflammation. New book : “Inflammation-body alert system” Dangles ed., launching April 2019. Visit website: https://www.aisa-tx.com/company/ patrizia-d
Lifeboat Foundation Bios: Dr. Patrizia Anna d’Alessio Skip to content Lifeboat Foundation: Safeguarding Humanity About Blog Boards Programs Reports Papers Donate Join Us Newsletter Quotes Store Press Releases Toggle sitemap Lifeboat Foundation Sitemap icon-search Main Areas Home About Boards Blog Programs Reports Papers Donate Join Us Newsletter Quotes Store Press Releases Current Programs AIShield AsteroidShield BioShield InfoPreserver InternetShield LifePreserver LifeShield Bunkers NanoShield ScientificFreedomShield SecurityPreserver Space Habitats X-Risks Network Cool Places A-PRIZE A … gs Outreach Partnerships Rosetta@Home Volunteer Work About Us Bitcoin Endowment Fund Boards Board of Directors Contact Us Donor List FAQ Finances Guardian Award Interactive Friendly AI Logo Memorial Board Mission Statement Procedures Staff Supplemental FAQ Timeline More Programs AlienShield AntimatterShield BioPreserver BlackHoleShield ClimateShield CommPreserver EnergyPreserver GammaRayShield NeuroethicsShield NuclearShield ParticleAcceleratorShield PersonalityPreserver Seed … ecules corresponding to her selection criteria (3 patents filed). Following the Award of the Ministry of research and Technology of France for Innovative Research in 2005, she founded AISA Therapeutics , a startup company promoting the research and development of anti-inflammatory / anti-senescence molecules. One of these molecules and its major metabolite have been validated for their anti-inflammatory activity in pre-clinical models in rodents and have shown impressive anti
Instagram Instagram Log In Sign Up Close Never miss a post from aisa_moleculum Sign up for Instagram to stay in the loop. Sign up Log in aisa_moleculum • Follow More options aisa_moleculum 34w A FOCUS ON OUR FOUNDER ✅ Patrizia Anna d'Alessio is an italian doctor specialized in clinical and laboratory hematology (University of Milan). She continued her studies in Utrecht (The Netherlands), where she obtained her PhD (science thesis) in hemorheology (1989) that is the science of the physicam behaviour of blood being a liquid quite different from water, not following newtonian laws. ✅Recruit … as well as and stress-accelerated inflammation and aging. ✅She won the national award for innovative research in 2005, followed by the foundation of the start-up AISA Therapeutics, (AISA being the acronym of Anti-Inflammatory-Senescence-Actives) which started with a large portfolio of patents in Europe, China, and the United States. The RISTOMED clinical study (2009-2013) of the European Community's 7th Framework Project on “healthy aging by nutrition” validates her disc
Prof. Dr. Patrizia D'Alessio | Founder of AISA Therapeutics Our Products All our products Explore our anti-inflammatory & wellness solutions Discover Anti-inflammatory capsules AISA Moleculum 120€ Best seller AISA routine Discover the routine to implement Top Action Science Science & Evidence Silent inflammation Stress & cortisol Gut, brain & skin axis Senescence & inflammaging D-Limonene Advice Approach Founder AISA Vision Research & Innovation Partners Help Support & FAQ Delivery Returns & Refunds Contact EN FR 0 AISA moleculum Founder Patrizia D'ALE … gnition by academic and institutional bodies Awards & Distinctions National Award for Innovative Business Creation 2005 · Ministry of Research (France) · Awarded for the creation of AISA Therapeutics and the promotion of fundamental scientific research in marketable products. Appointment as Professor 1998 · Faculties of Medicine Paris 5 & Paris 11 · Recognition of the excellence of his research work in cell biology and his expertise in chronic inflammation and aging.
#aisatherapeutics #senescence #inflammatory #antiinflammatory #science #aging #antiaging | Patrizia D'Alessio LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign … as well as and stress-accelerated inflammation and aging. ✅She won the national award for innovative research in 2005, followed by the foundation of the start-up AISA Therapeutics, (AISA being the acronym of Anti-Inflammatory-Senescence-Actives) which started with a large portfolio of patents in Europe, China, and the United States. The RISTOMED clinical study (2009-2013) of the European Community's 7th Framework Project on “healthy aging by nutrition” validates her discovery
Pr Patrizia D'Alessio REPLAYS SPEAKERS EXHIBITORS PREVIOUS EDITION DOWNLOAD THE BOOK PPD Pr Patrizia D'Alessio AISA Therapeutics CEO Description Pr Dr Patrizia Anna d'Alessio, MD PhD CEO AISA Therapeutics Cell Biology Faculties of Medicine Université Paris René Descartes & Université Paris Sud-11 1984-2011 University of Milan (IT), University of Utrecht (NL), King's College London (UK), INSERM Paris (FR) CNRS Gif-sur Yvette (FR) Patrizia A d'Alessio, graduated in medicine (MD) from the University of Milan (Italy), specializing in internal medicine-hematology, clinical and laboratory medic
A new study from Sudipta Bar, Kenneth Wilson, Tyler A. | Giulio Maria Pasinetti, MD, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
About | Longevity Summit Dublin 2026 About | Longevity Summit Dublin 2026 about Longevity Summit Dublin 2026. The official website for the Longevity Summit Dublin 2026, a premier science-led. Pages Admin Bank Details — Admin Bank Details on Longevity Summit Dublin 2026. The official website for the Longevity Summit Dublin 2026, a premier science-led. Admin Dinner Invites — Admin Dinner Invites on Longevity Summit Dublin 2026. The official website for the Longevity Summit Dublin 2026, a premier science-led. Programme — Programme on Longevity Summit Dublin 2026. The official website for the Long
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
World BI Success Stories | Our Conferences Highlights --> × --> --> --> Home About Us Conferences Digital Health Drug Discovery Clinical Trials Clinical Trial Supply Pharma Packaging Pharma Supply Chain Brand Protection World Technology Congress --> Hotel Technology Advanced Air Mobility --> --> In Person Conferences --> --> Digital Health --> Drug Discovery --> Clinical Trials --> Clinical Trial Supply --> Pharma Packaging --> Pharma Supply Chain --> Brand Protection --> World Technology Congress --> Hotel Technology --> Advanced Air Mobility --> --> --> Webinars
Portfolio Team Strategy News Investor Login Portfolio Team Strategy News Investor Login Portfolio Filters Filter by Company Status Acquired IPO Private Public Therapeutic Area Autoimmune Bone Cardiometabolic CNS GI/Liver Oncology Ophthalmology Orphan Diseases Other Respiratory Vaccines Modality ADC Biologics Biologics Cell Therapy Drug-Device Combo Gene Therapy Pharma Services Radiopharm Small Molecules Year All 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2000 1999 1998 1997 1996 1993 1991 Clear All Company (A-Z) Statu … pment company with two novel mechanisms to treat IgA nephropathy Frazier Public Fund’s first investment was in Chinook, and Frazier continued to build its position through multiple financings to support the development of Atrasentan and BION-1301 for IgA nephropathy. Frazier also co-led a spinout of Chinook into a new private company, SanReno Therapeutics. Chinook was acquired by Novartis in 2023. Acquired by Novartis in 2023 Status Acquired Therapeutic Area Autoimmune Modali … eloping novel therapies for chronic lung diseases Frazier Life Sciences’ Public Fund invested in Verona Pharma to support the advancement of ensifentrine, a first-in-class dual PDE3 and PDE4 inhibitor for chronic obstructive pulmonary disease (COPD) and other respiratory indications. The company’s lead program demonstrated clinically meaningful improvements in lung function and symptom control in pivotal Phase 3 trials. Verona completed its U.S. regulatory filing in 2024, wit … zier Life Sciences has been named as an investor in press releases – for public fund holdings please see our Form 13F filings. Longstanding healthcare investment firm partnering with and building companies developing novel therapeutics from seed to publics. Portfolio Team Strategy News Investor Login Palo Alto San Diego Boston Seattle Investor Login © 2026 Frazier Life Sciences Privacy Policy Terms of Use Back to Top Google Maps Palo Alto 1001 Page Mill Road Building 4, Suite
Pharma Business Development & Licensing Conference Home About US Summits Pharma Partnering US Summit 2026 19th/20th November 2026 - Boston, MA Pharma Partnering US Summit 2027 12th/13th May 2027 - San Diego, CA EU Summits Pharma Partnering EU Summit 2026 20th/21st May 2027 - Basel, Switzerland BD&L Training Course Registration Contact One to One Meetings Your browser does not support the video tag. Pharma Partnering US Summit 19 TH -20 TH November 2026 Boston | Massachusetts | USA Pharma Partnering US Summit 12 TH -13 TH May 2027 San Diego | California | USA Pharma Partnering EU Summit 20 TH -
Portfolio | Sanofi Ventures Skip to main content Home Team Approach Portfolio News SANOFI VENTURES © 2026 Our Portfolio IPO / Acquired Investments Biotherapeutic Digital Health All abcuro Close Private Newton, MA www.abcuro.com Developing treatments for autoimmune and cancer indications. Abcuro is a biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1 (killer cell lectin-like receptor G1). The company is advancing ABC008 toward the clinic, a first-in-class anti-KLRG1 … ence. Press releases Evidation Extends Collaboration with Sanofi to Develop and Apply Real-World Evidence Jan 10, 2022 Read More Evidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform. Mar 25, 2021 Read More Evidation Raises $45 Million Series D, Hires CCO To Accelerate Commercial Momentum and Expand Into Virtual Health Jul 01, 2020 Read More Evidation Health and BARDA Partner on Early Warning System for COVID-19 Jun 04, 2020 Read More Evidation … erited Metabolic Disorders Jul 29, 2014 Read More Fate Therapeutics Submits IND Application for the Clinical Development of PROHEMA(R) in Inherited Metabolic Disorders Jun 30, 2014 Read More Fate Therapeutics to Highlight Potential Clinical Applications of Ex Vivo Hematopoietic Cell Modulation at 12th International Cord Blood Symposium Jun 05, 2014 Read More Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients … eutics Raises $4 million in Seed Funding Co-led by Sanofi Ventures and JDRF T1D Fund Apr 09, 2020 Read More Icosavax Close Acquired Seattle www.icosavax.com Focusing on developing safe and effective vaccines against infectious diseases. Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs and reduce healthcare costs. The company was founded on breakthrough computationally-designed virus like parti … res $30M in Series C Funding led by Sanofi Ventures and ALIVE Israel HealthTech Fund to Build Future Model of Patient Support. Feb 25, 2021 Read More Minervax Close Private Copenhagen, Denmark minervax.com Developing a prophylactic vaccine against Group B Streptococcus. Minervax is a clinical stage biotechnology company developing a prophylactic
Instagram Instagram Log In Sign Up Close Never miss a post from aisa_moleculum Sign up for Instagram to stay in the loop. Sign up Log in aisa_moleculum • Follow More options aisa_moleculum 41w AISA MOLECULUM COMBINES ANTI-INFLAMMATORY, ANTI-STRESS AND ANTI-AGING PROPERTIES AISA moleculum (AISA Therapeutics) is a unique anti-inflammatory nutraceutical based on the molecule AISA 5203-L (d-Limonene). Its action is fully in line with a bioguided approach to cellular aging. Scientifically validated mechanisms of action — Inhibition of endothelial cell adhesion molecules (ICAM-1, VCAM1, PECAM-1, E-s … ulation in elderly people in human studies (RISTOMED project) — Topical or oral application to the skin shows anti-aging, anti-redness, extreme moisturizing, and improved elasticity effects Why make it a pillar of longevity? — Epigenetic targeting of aging: acting on chronic inflammation (inflammaging) prolongs healthspan. — Dual action: nervous system (stress reduction, dopamine boost) + tissue support (anti-inflammatory, anti-senescence) — Internal/external synergy: oral su
Portfolio - OrbiMed About Us Portfolio Leadership News & Insights Contact EN CH --> Portfolio Gene Editing. AI-guided Drug Discovery. Liquid Biopsy. The future of health sciences is closer than you think. Many technologies with the potential to cure disease are advancing rapidly. How long can healthy humans live, 120 years? 150 years? Our portfolio companies are working hard to find out. Filter by Sector Biopharmaceutical Diagnostics/Tools Healthcare IT Healthcare Services Medical Device Filter by Region Asia Europe / MENA North America Sort Alphabetical Newest Oldest Clear All Filters Clear A … lter by Region Asia Europe / MENA North America Sort Alphabetical Newest Oldest Apply Load More Referenced companies reflect current portfolio holdings of OrbiMed-managed private equity funds. There is no assurance that any securities discussed herein are, or will remain, in an OrbiMed-managed portfolio. Any such securities do not represent an entire fund or portfolio and it should not be assumed that they were or will be profitable, or that the investment recommendations or … nhancing medication safety & efficacy, DIH aspires to be a premier technology & application platform leader in Rehab & Sports Medicine (RSM) and Intelligent Medication & Supply (IMS) businesses, enabled by passionate teams working around the globe. Sector Medical Device Region Asia link link Disc Medicine Disc Medicine is a clinical-stage biopharmaceutical company developing treatments for hematologic disorders. Disc Medicine is building a unique portfolio of innovative, firs
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multi … s for the treatment of Rett syndrome and GAN. The future options to potentially apply Astellas' global R&D, manufacturing and commercialization capabilities in gene therapy to Taysha's innovative AAV gene therapy development programs for genetic diseases of the central nervous system (CNS) create the opportunity for the two companies to enhance the development of novel treatment options for patients with Rett syndrome and GAN, who have serious unmet medical needs. Under t … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Portfolio Companies – ChiesiVentures Skip to content Menu Home Investment Focus Small Molecules and Biologics Advanced Therapies Reformulation Technological Platform and Devices Disease discovery, diagnosis and management Investments Portfolio Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan Portfolio Companies Portfolio Companies Chiesi Ventures invests in innovative biotech companies developing treatments for rare diseases. MIRUM PHARMACEUTICALS Mirum Pharmaceuticals is developing a compound, maralixibat, to treat Alagille syndro … Companies Strategic Connections Pappas Capital News Connect Team and Governance Submit your business plan
%PDF-1.3 %���� 4 0 obj > endobj xref 4 49 0000000016 00000 n 0000001524 00000 n 0000001620 00000 n 0000002092 00000 n 0000002226 00000 n 0000002358 00000 n 0000003081 00000 n 0000003419 00000 n 0000004036 00000 n 0000005486 00000 n 0000005889 00000 n 0000007270 00000 n 0000008758 00000 n 0000010341 00000 n 0000011817 00000 n 0000013279 00000 n 0000014688 00000 n 0000015842 00000 n 0000015955 00000 n 0000016066 00000 n 0000016135 00000 n 0000016516 00000 n 0000016770 00000 n 0000016922 00000 n 0000016947 00000 n 0000017254 00000 n 0000017323 00000 n 0000017801 00000 n 0000018053 00000 n 0000018 … eam 300.00 300.00 Inches AdobeARM ReferenceStream 300.00 300.00 Inches AdobeARM application/pdf Adobe PDF Library 8.0 False endstream endobj 3 0 obj > endobj xref 0 4 0000000000 65535 f 0000559697 00000 n 0000559748 00000 n 0000578912 00000 n trailer ]>> startxref 116 %%EOF
%PDF-1.6 %���� 427 0 obj > endobj 446 0 obj >/Filter/FlateDecode/ID[ ]/Index[427 31]/Length 107/Prev 1152006/Root 428 0 R/Size 458/Type/XRef/W[1 3 1]>>stream h�bbd```b``="3@$��6Dn3��;�-� ��& ��0��#H��X�~0��\��]��["E�@$w$�� ������h�I2�����;@�j5 endstream endobj startxref 0 %%EOF 457 0 obj >stream h�b```�6ɹ � �� ea� pd``1d�1```d�L,@AFS�-S�̷1��8��%Ep�U ����=��400��1 ���q�������M� X�9^r`�gڭ�\�o��?@h+#C})�|��w/ /�g:�8��)晑nv�uS�ɱ�6�( �\��z�͗G���x h#ӡr#�Zx$�A�e�|�o 2] ��ly*`�H��c��ۀ�,kV%L[�k�$04���Y&u� ۼ�� 7���¤M��|@� ��B-�� xb��� ��::*:�L::� … R����c�+�H�R��09�O�8C�`� �|�� �Z�ˀ��u���9(���4�v���ۃ��.sB�Y�Bo8� }�E��g��rFp�}\�ڙ*|ݜ�}§ 4�r��X���y�i��z."U#2��#J�l���=�&C!������#E��İ)E[�\.��(V���r����\�����Q(6�7���|� y�V�8 ��l���V�e�,h�ȳT�b2�T� ���|���f�` I]���o\K�k������Q���� &]� ��Ct2~�췴�hAӄ��:_��p.3���mzb��S����1�1DQ����I2�TC ��Q�-?v �I Ecda��#�+~�5�jVojǮ]�.� U$~���+��r�J�/����刚r�)\XYF�f�QH�~�"�XF� ����+�y��V��[���)�/�;u�z�3�fBA�D�����QVxl�EBj��x�v���(">%4�ӳ$Y��Ԝ�Ҝ}���f� � 7o�9�E6�6� … m 2014-08-19T12:35:23+02:00 2014-08-19T12:35:23+02:00 2014-08-19T12:35:23+02:00 application/pdf uuid:ef6c897a-b4f6-1f4a-b00b-a72a18bc961a uuid:8cd74400-d944-694e-ad83-3a23bf926723 endstream endobj 459 0 obj > endobj 460 0 obj >stream hބα �@�_�?��d��BHci��X I9�.����հޅ+XC���1������\�����(��E�i$��Q���w�G�hDE nBc��9p���?~lUF* endstream endobj 461 0 obj >stream h�214Q0P����+�-�6P014�L�,30�� �41c�� �� endstream endobj 462 0 obj >/Filter/FlateDecode/ID[ ]/Index[46 1 49
%PDF-1.6 %���� 1489 0 obj > endobj 1539 0 obj >/Filter/FlateDecode/ID[ ]/Index[1489 94]/Info 1488 0 R/Length 190/Prev 4988116/Root 1490 0 R/Size 1583/Type/XRef/W[1 3 1]>>stream h�bbd```b`��� U �e"�d���� ��2��� "9����`� LV��O� @���,� ��l� X�t�~l�1 ��V�� Dz��p��E���_!���Y}�"�$��-`�̇A�c.�d��`���H�� UU�_�~d���f�ٳ��N$�\$�. �w;е� � �b` q�������$N endstream endobj startxref 0 %%EOF 1582 0 obj >stream h��WkTW �3���� D ,"V��Ix�L��S*��+��HP� ��&���ʊ�B��U8l �$P�څV�Z���T�x\QD���h�w& $�����s�������w���� (Pi�L_v� ,� �e4.F �h2,��`���TN��+J�#j �P]8����p@ � J����`�hd�E�T�T��8 … 6DC6F61D5968C5 2013-04-03T17:39:32+02:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.photoshop derived converted from application/vnd.adobe.photoshop to image/epsf saved xmp.iid:61C1648535206811A0EA93147C2E56BB 2013-04-03T17:39:55+02:00 Adobe Photoshop CS5 Macintosh / Print False False Adobe PDF library 8.00 4 Coated FOGRA27 (ISO 12647-2:2004) endstream endobj 1527 0 obj >stream Adobe PDF library 9.90 2013-05-22T16:49:26+02:00 2013-0 … 41292d5a0143 uuid:646f2e62-0847-11dc-a413-0016cb3a0cda proof:pdf converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:01801174072068118083979CF9705CC5 2012-05-04T09:37:27+02:00 Adobe Illustrator CS5.1 / saved xmp.iid:F77F1174072068118A6DC90A13437F83 2013-05-22T16:49:24+02:00 Adobe Illustrator CS5 / uuid:9be4b480-5f9a-4c4b-85af-dddff3cdaae4 xmp.did:01801174072068118083979CF9705CC5 uuid:646f2e62-0847-11dc-a413-0016cb3a0cda proof:pdf applicati … �XUD~*���h�� X���G�|�ַ � {�J�� 1ڀW�M~�R�� endstream endobj 7 0 obj >stream application/pdf LOGO GENEPOLE Adobe Illustrator CS5 2013-05-24T11:00:39+02:00 2013-05-27T14:09:03+02:00 2013-05-27T14:09:03+02:00 xmp.did:01801174072068118A6DD88357A5B709 uuid:15aaa572-d61d-cc49-8309-c6490ff6e614 uuid:871E1DB19D3D11E28C52B4DF67FDDFC1 proof:pdf uuid:5740c887-11ef-4baa-ae58-2bbbd75434bc uuid:871E1DB19D3D11E28C52B4DF67FDDFC1 uuid:871E1DB19D3D11E28C52B4DF67FDDFC1 saved xmp.iid:0180117 … -��� ��j�^{��i1�)���h�?�=.����`�����;� 7 endstream endobj 253 0 obj >stream application/postscript CEA_logotype_4c Adobe Illustrator CS3 2012-03-23T15:47:17+01:00 2012-03-23T15:47:17+01:00 2012-03-23T15:47:17+01:00 256 212 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/
Curriculum Vitae - AISA Therapeutics EN English Deutsch Français Español Português Italiano Român Nederlands Latina Dansk Svenska Norsk Magyar Bahasa Indonesia Türkçe Suomi Latvian Lithuanian český русский български العربية Unknown Login to YUMPU News Login to YUMPU Publishing TRY ADFREE Discover products News Publishing Magazines Create ePaper Login to YUMPU News Login to YUMPU Publishing × Attention! Your ePaper is waiting for publication! By publishing your document, the content will be optimally indexed by Google via AI and sorted into the right category for over 500 million ePaper r … ity as Industrial Consultant 2007-2009 BioSerae (out licensing of nutraceutical application <strong>AISA</strong> patent) 1998-2001 Bio-Mérieux (proof of concept for vaccine cervical cancer) 1996-1998 Ipsen-Beaufour, Lipha-Merck, Pfizer (anti-inflammatory research) 1994-1996 l'Oréal (biology of aging) 1992-1996 Bioxytech and OXIS Int SA (biology of oxidative stress, GPx mimics) EDUCATION DUCATION Office Inserm U935, Université Paris-Sud 11 Hôpital Paul Brousse 948
US20140255888A1 - Optical neuroinformatics - Google Patents US20140255888A1 - Optical neuroinformatics - Google Patents Optical neuroinformatics Download PDF Info Publication number US20140255888A1 US20140255888A1 US13/815,574 US201313815574A US2014255888A1 US 20140255888 A1 US20140255888 A1 US 20140255888A1 US 201313815574 A US201313815574 A US 201313815574A US 2014255888 A1 US2014255888 A1 US 2014255888A1 Authority US United States Prior art keywords path metric target individual icon Prior art date 2013-03-11 Legal status (The legal status is an assumption and is not a legal conclusion. Goo … s and makes no representation as to the accuracy of the status listed.) Granted Application number US13/815,574 Other versions US9380976B2 ( en Inventor Matthew E. Stack Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Neurosync Inc Original Assignee Sync Think Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google ha … sted.) 2013-03-11 Filing date 2013-03-11 Publication date 2014-09-11 2013-03-11 Application filed by Sync Think Inc filed Critical Sync Think Inc 2013-03-11 Priority to US13/815,574 priority Critical patent/US9380976B2/en 2013-08-09 Assigned to SYNC-THINK, INC. reassignment SYNC-THINK, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STACK, MATTHEW E. 2014-09-11 Publication of US20140255888A1 publication Critical patent/US20140255888A1/en 2016-01-1 … YNC-THINK, INC. QUIT-CLAIM ASSIGNMENT Assignors: HALCYON BIGAMMA LLC 2016-07-05 Application granted granted Critical 2016-07-05 Publication of US9380976B2 publication Critical patent/US9380976B2/en 2024-06-13 Assigned to NEUROSYNC, INC. reassignment NEUROSYNC, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SYNC-THINK, INC. Status Active legal-status Critical Current 2033-05-25 Adjusted expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignmen … tion Deficit Disorder) and ADHD (Attention Deficit Hyperactivity Disorder). ADD Application Deficit Disorder ADHD Adtention Deficit Hyperactivity Disorder this invention does not require the introduction of any new technology on the hardware or in data collection methods. the invention is instead an improvement on the analysis of the data files c
Workshop ILSA “𝐋𝐎𝐍𝐆𝐄𝐕𝐈𝐓𝐘 &... - Dr. Massimo Spattini Facebook Log In Dr. Massimo Spattini's Post Dr. Massimo Spattini Verified account May 29 at 7:11 AM · Shared with Public Workshop ILSA “𝐋𝐎𝐍𝐆𝐄𝐕𝐈𝐓𝐘 & 𝐑𝐄𝐆𝐄𝐍𝐄𝐑𝐀𝐓𝐈𝐕𝐄 𝐏𝐄𝐏𝐓𝐈𝐃𝐄 𝐓𝐇𝐄𝐑𝐀𝐏𝐘” Parma, Novotel Parma Centro 𝟐𝟎-𝟐𝟏 𝐆𝐢𝐮𝐠𝐧𝐨 𝟐𝟎𝟐𝟔 @ longevityscience.eu INFO/ISCRIZIONI https://longevityscience.eu/index.php/home-mob... #longevity #longevità #peptides #healthy #peptidetherapy +2 All reactions: 33 1 comment 4 shares Like Comment Most relevant Dott Umberto Villanti Molto bella, utili
BioPharma Deals — BD&L Summit 2026 | Munich, 24th & 25th November Home About EU Conferences ▾ BioPharma Deals 2026 24th & 25th November 2026 Prices BD&L Training Contact Register Now Home About BioPharma Deals 2026 — Munich BD&L Training Course Registration Contact Register Now → Overview Agenda Speakers Programme Venue Partners Testimonials Who Attends Logistics Registration BD&L Summit · Munich · 24th & 25th November 2026 BioPharma Deals BD&L Summit Munich 2026 Europe's most focused gathering of life sciences dealmakers. Two intensive days of hi … y, Allen & Overy Law Firm ... --> Who Attends A Room Full of Decision-Makers We apply a rigorous curation process to ensure every attendee holds genuine deal authority. No passengers — every person in the room can initiate and advance a real deal. 01 Chief BD Officers & VP Business Development Senior BD leaders from Big Pharma, Specialty Pharma, and mid-sized biopharmaceuticals responsible for licensing and partnership strategy at portfolio level. Licensing · Partnering 0 … ital Signature * Confirm accuracy of information Security hCaptcha verification Submit Registration Processing... * Required. By submitting, you agree to our Terms and consent to be contacted. We never share your data. SSL Encrypted • GDPR Compliant Registration Confirmed! Thank you for registering for BioPharma Deals 2026. You'll receive a confirmation email shortly with your meeting platform access and next steps. Return to Home Contact Support Munich · 24–25 November 2026
Book Your Seat – Drug Discovery Conference US | DDIP --> Agenda --> Testimonials --> Venue --> --> Get Involved Heard From? Google Search Social Media Sales Person Through Newsletter Other (Please Specify) Submit Get Involved --> --> Home --> --> About Speakers Agenda Sponsors Venue Who Attends --> Networking Dinner --> --> Testimonials --> Gallery --> --> --> Venue --> --> Contact Us --> Content Hub --> --> --> --> Loading... --> --> --> Buy Tickets --> March 10 - 11, 2026 San Diego, California Drug Discovery Innovation Programme Transforming Research into Reality! Buy Tickets --> REGISTER • … --> --> --> --> --> --> --> --> --> --> --> --> --> --> Joelle Gola --> Senior Application Scientist --> CAS - a division of the American Chemical Society --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> Zofia Świątczak --> Head of Sales - Europe --> EditCo --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> Angelo Lanzilotto --> Solution Sales Specialist - Digital Chemistry --> Merck KGaA --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> … --> --> --> --> --> --> --> --> --> --> --> --> --> --> Joelle Gola --> Senior Application Scientist --> CAS - a division of the American Chemical Society --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> Zofia Świątczak --> Head of Sales - Europe --> EditCo --> --> --> --> --> --> --> --> --> --> --> --> --> --> --> Angelo Lanzilotto --> Solution Sales Specialist - Digital Chemistry --> Merck KGaA --> --> --> --> --> --> --> --> Become a Speaker --> --> --> --> Jo … will take place on Oct 8, 2024 (7-10pm) as part of the DHAI Summit program. The deadline has passed. We are no longer accepting submissions. Thank you for your interest! --> --> --> --> --> MedTech AI Startup Pitch Contest --> The DHAI Summit in partnership with SkyMedAI are excited to present the MedTech Pitch Contest (Shark Tank-style). Brace yourself for a unique opportunity to gain exposure, make connections, and propel your venture to new heights. The Pitch Contest will … will take place on Oct 8, 2024 (7-10pm) as part of the DHAI Summit program. The deadline has passed. We are no longer accepting submissions. Thank you for your interest! --> --> --> --> --> --> --> Calling Startups & Entrepreneurs! DDIP is excited to present a Biotech Pitch Contest, offering a unique opportunity for startups to showcase their inn
US20140154650A1 - Application of smooth pursuit cognitive testing paradigms to clinical drug development - Google Patents US20140154650A1 - Application of smooth pursuit cognitive testing paradigms to clinical drug development - Google Patents Application of smooth pursuit cognitive testing paradigms to clinical drug development Download PDF Info Publication number US20140154650A1 US20140154650A1 US13/694,461 US201213694461A US2014154650A1 US 20140154650 A1 US20140154650 A1 US 20140154650A1 US 201213694461 A US201213694461 A US 201213694461A US 2014154650 A1 US2014154650 A1 US 2014154650A1 Aut … s and makes no representation as to the accuracy of the status listed.) Granted Application number US13/694,461 Other versions US9265458B2 ( en Inventor Matthew E. Stack Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Neurosync Inc Original Assignee Sync Think Inc Priority date (The priority date is an assumption and is not a legal conclusion. Google ha … sted.) 2012-12-04 Filing date 2012-12-04 Publication date 2014-06-05 2012-12-04 Application filed by Sync Think Inc filed Critical Sync Think Inc 2012-12-04 Priority to US13/694,461 priority Critical patent/US9265458B2/en 2013-08-09 Assigned to SYNC-THINK, INC. reassignment SYNC-THINK, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STACK, MATTHEW E. 2014-06-05 Publication of US20140154650A1 publication Critical patent/US20140154650A1/en 2016-01-1 … YNC-THINK, INC. QUIT-CLAIM ASSIGNMENT Assignors: HALCYON BIGAMMA LLC 2016-02-23 Application granted granted Critical 2016-02-23 Publication of US9265458B2 publication Critical patent/US9265458B2/en 2024-06-13 Assigned to NEUROSYNC, INC. reassignment NEUROSYNC, INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SYNC-THINK, INC. Status Active legal-status Critical Current 2033-10-06 Adjusted expiration legal-status Critical Links USPTO USPTO PatentCenter USPTO Assignmen … Definitions This invention relates to the clinical drug development process to apply the use of neuropsychological smooth pursuit tracking tests for providing quantifiable measure of cognitive behavior and function for detecting the efficacy of neuro-pharmaceutical compounds. the first and the most commonly used cognitive testing paradigm is the
Expert Speakers | The Longevity Show 2026 Skip to content Get the latest on the event, plus insights shaping the future of health and longevity, and 15% off your tickets! → What’s On Close What’s On Open What’s On What’s On Explore the speakers, stages and brands shaping how we live better for longer. Get Tickets Stages & SUmmits Headliner Stage Women’s Health Summit Discover Stage Edelman Longevity Lab B2B conference Headliner Stage Women’s Health Summit Discover Stage Edelman Longevity Lab B2B conference The Expo Speakers Evenings The Expo Speakers Evenings Experiences Close Experiences … nic® Carolyn Paul EMEA Chair of Health Edelman Max Gottschalk Partner Longevity Fund by Clinique La Prairie Alexandra Bause Co-Founder and Venture Partner Apollo Health Ventures Niko Waesche Co-Founding Partner GMPVC Group Abby Levy Managing Partner and Founder Primetime Partners Brenda Irwin Managing Partner Relentless Venture Fund Lyne Landry Founding and Managing Partner AgeTech Capital Jocelyn Wittstein Co-Author The Complete Bone and Joint Health Plan Livia Solustri Foun … ssion Meet the Team Plan your Visit Contact Us Volunteer Programme Press Access Application Our Mission Meet the Team Plan your Visit Contact Us Volunteer Programme Press Access Application Follow Us Instagram Linkedin Get 15% off Get Tickets Stay In The Loop Get all the latest updates from The Longevity Show delivered straight to your inbox. Submit * By submitting your email, you opt in to receive communications from The Longevity Show. You may unsubscribe at any time. Terms
Controlling Inflammation for Better Surgical Results with AISA Care | AISA Therapeutics - Anti-Inflammatory Senescence Actives posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Li
Infiammazione, D’Alessio (AISA THERAPEUTICS): il punto sugli studi più recenti | Sanità33 Login con » ACCEDI | REGISTRATI Toggle navigation Politica sanitaria Governo e Parlamento Interviste Europa Indagini Regioni e Asl Ricerca e cura Terapia Digital Mercato Lavoro e professioni Medici Ospedali Speciali e servizi Corsi Eventi Speciali Rubriche Toggle navigation Politica sanitaria Ricerca e cura Lavoro e professioni Speciali e servizi Governo e Parlamento Interviste Europa Indagini Regioni e Asl Terapia Digital Mercato Medici Ospedali Corsi Eventi Speciali Rubriche Inserisci la chiave di ricer … tudio clinico RISTOMED finanziato dal programma quadro FP7 della Comunità EU – “grant agreement 222230” ha validato i risultati sull’uomo e avviato l’integratore. TAG: INTEGRATORI , INVECCHIAMENTO Se l'articolo ti è piaciuto rimani in contatto con noi sui nostri canali social seguendoci su: Oppure rimani sempre aggiornato in ambito farmaceutico iscrivendoti alla nostra newsletter! ISCRIVITI POTREBBERO INTERESSARTI ANCHE 24/06/2026 Governo e Parlamento Prontuario Aifa, il Gove
Patrizia D'Alessio the CEO of AISA THERAPEUTICS will be speaking at the first-ever International Longevity Summit (ILS) Africa, gearing up to make its mark as a trailblazing event focused on the… | Ósìnákáchī Àkùmà Kálū, MBA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update yo
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Innovation for health is not dangerous Discover AISA Therapeutics AISA Therapeutics Founded in October 2005 by Pr Dr Patrizia Anna d’Alessio, MD PhD – AISA Therapeutics, which is an acronym for Anti-Inflammatory Senescence Actives, is dedicated to the development and commercialization of non-toxic anti-inflammatory / anti-senescence products, based on a novel concept. Vision & Mission Inflammation is at the basis of aging. AISA research and prod
Company – AISA Therapeutics Salta al contenuto Home Events References R&D Company Products Home Events References R&D Company Products Company OVERVIEW AISA, acronym of Anti Inflammatory Senescence Actives, is a start-up created by Pr d’Alessio following her national award for Innovation. Focused on the research and development of new anti-inflammatory / anti-senescence molecules as an alternative to steroidal and non-steroidal anti-inflammatory drugs and anti-TNF drugs, AISA Therapeutics displays a consequent patent portfolio covering about 50 claims in human and animal
%PDF-1.4 %���� 493 0 obj > endobj xref 493 101 0000000016 00000 n 0000004416 00000 n 0000004482 00000 n 0000005037 00000 n 0000005151 00000 n 0000005813 00000 n 0000006419 00000 n 0000007037 00000 n 0000007664 00000 n 0000008280 00000 n 0000008888 00000 n 0000009574 00000 n 0000009842 00000 n 0000010008 00000 n 0000012759 00000 n 0000013109 00000 n 0000013531 00000 n 0000013964 00000 n 0000018624 00000 n 0000019235 00000 n 0000019914 00000 n 0000020533 00000 n 0000021502 00000 n 0000021537 00000 n 0000021566 00000 n 0000021641 00000 n 0000024113 00000 n 0000024444 00000 n 0000024510 00000 n 00 … ,26,27,28,30;7E3248F0513FE72FCAD29D71BC462D67 endstream endobj 26 0 obj >stream application/postscript logo + acriter + drug disc cons en ligne Adobe Illustrator CS3 2008-05-16T10:31:37+02:00 2008-05-16T10:31:38+02:00 2008-05-16T10:31:38+02:00 256 140 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YE … B971D86 uuid:8051B8EFD628DC1182ABEC4B0B971D86 endstream endobj 55 0 obj >stream application/postscript Adobe Illustrator CS3 2008-05-16T10:53:23+02:00 2008-05-16T10:53:24+02:00 2008-05-16T10:53:24+02:00 196 256 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUFBgkGBQYJCwgGBggLDAoKCwoK
DBAMDAwMDAwQDA4PEA8ODBMTFBQTExwbGxscHx8fHx8fHx8fHwEHBwcNDA0YEBAYGhURFRofHx8f
Hx8fHx8fHx8fHx8fHx8fH … Rsf/NWP+h/V/zR8wv8saf+d9hVIPy382pN
GzWqUVgT+9j6A/PJQ7A1YIPCPmGMu19ORz+wv//Z application/postscript xmp.iid:74117FD9200711688EF1E22FE867781C xmp.did:74117FD9200711688EF1E22FE867781C uuid:f468ad20-c360-11dc-85e7-000d932ea2d6 uuid:f468ad20-c360-11dc-85e7-000d932ea2d6 uuid:f468ad20-c360-11dc-85e7-000d932ea2d6 uuid:f468ad20-c360-11dc-85e7-000d932ea2d6 saved xmp.iid:74117FD9200711688EF1E22FE867781C 2009-05-07T14:46:55+02:00 Adobe Illustrator CS4 / 1 True False 209.999929 296.99 … ,26,27,28,30;7E3248F0513FE72FCAD29D71BC462D67 endstream endobj 88 0 obj >stream application/postscript Adobe Illustrator CS3 2008-05-16T10:39:02+02:00 2008-05-16T10:39:02+02:00 2008-05-16T10:39:02+02:00 256 52 JPEG /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQEBAUEBgUF
--> --> Drug Discovery & Preclinical Summit | 25-26 June 2025 - Amsterdam --> --> Home --> Browse Events --> --> View All Categories --> View All Events --> --> --> Browse Events View All Categories View All Events About Testimonials Blogs Solutions Venture Capital Connections Lead generation Business Development Consulting Contact Us Book a Demo Precision in Drug Discovery & Preclinical Summit Amsterdam-Europe --> --> Previous Next Precision in Drug Discovery & Preclinical Summit Amsterdam-Europe Collaboration, Innovation & Precision Medicine Precision Evolution Global Conferences Drives Inno … interactive sessions, all designed to provide practical knowledge that you can apply in your clinical trial work immediately. Learn More --> --> Precision Summit Different--> --> Why Attend Precision Evolution Global Conferences, Events and Summits - **Stay Informed:** Keep up-to-date with the latest regulatory changes, technological advancements, and industry trends that are transforming the landscape of drug development - **Professional Growth:** Elevate your expertise and … es (e.g. gmail, hotmail, yahoo) will result in your registration being refused. Submit Contact us to Speak or Join the Panel Full Name Email Address Please use your corporate/business email address. Personal addresses (e.g. gmail, hotmail, yahoo) will result in your registration being refused Submit Request the Agenda Full Name Email Address Please use your corporate/business email address. Personal addresses (e.g. gmail, hotmail, yahoo) will result in your registration being … ses (e.g. gmail, hotmail, yahoo) will result in your registration being refused Submit Join our newsletter to stay up to date on features and releases. Subscribe Now --> We care about your data in our privacy policy. Company About Us Solutions Our Events New Partners Testimonials Careers Support Contact PEG Book a Meeting Feedback Social Facebook X --> X LinkedIn Instagram YouTube TikTok © 2026 Precision Evolution Global Inc. All rights reserved. Terms Privacy Cookies --> &ti
On the Way to Longevity: How to Combat Neuro-Degenerative Disease | IntechOpen Books Book Series Journals Publish About News Author Panel Login Submit What is Open Access? Open Access is an initiative that aims to make scientific research freely available to all. To date our community has made over 100 million downloads. It’s based on principles of collaboration, unobstructed discovery, and, most importantly, scientific progression. As PhD students, we found it difficult to access the research we needed, so we decided to create a new Open Access publisher that levels the playing field for scie … ors and editors from 3,291 institutions spanning 160 countries, including Nobel Prize winners and some of the world’s most-cited researchers. Publishing on IntechOpen allows authors to earn citations and find new collaborators, meaning more people see your work not only from your own field of study, but from other related fields too. Content Alerts Brief introduction to this section that descibes Open Access especially from an IntechOpen perspective How it Works Manage prefer … Great Portland Street, London, W1W 5PF, UNITED KINGDOM Phone: +44 20 8089 5702 Submit Author Panel Sign in Terms and Conditions Privacy Policy Customer Complaints © 2026 IntechOpen. All rights reserved. CLOSE X IntechOpen Author/Editor? To get your discount, log in . Your cart Discounts available on purchase of multiple copies. View rates Subtotal €0.00 Local taxes (VAT) are calculated in later steps, if applicable. Checkout Support: [email protected] Please ensure Javas
Digitalis Ventures | News About People Human Health Animal Health News Notebook The Digitalis Group: Digitalis Ventures Digitalis Commons © 2026 Digitalis Ventures ALL NEWS LIFE SCIENCES NEWS HEALTH TECHNOLOGIES NEWS ANIMAL HEALTH NEWS DIGITALIS VENTURES NEWS Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. VARDA 5.13.2026 A plan to make drugs in orbit is going commercial MIT TECHNOLOGY REVIEW > EPIBIOLOGICS 4.20.2026 EpiBiologics Doses First Patient with EPI-326 Bispecific Antibody in Global Phase 1 Study for EGFR-Driven Solid Tumors BIOSP … ANCE > ONC.AI 10.24.2024 Onc.AI Awarded $2 Million National Cancer Institute Grant to Advance AI-based Clinical Decision Support for Metastatic NSCLC BIOSPACE > Alpha-9 Oncology 10.23.2024 Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals CNHI NEWS > TERRAY THERAPEUTICS 10.21.2024 Terray Therapeutics aims for the clinic by 2026 C&EN > TERRAY THERAPEUTICS 10.17.2024 Terray … genomes Nature Biotechnology > DIGITALIS VENTURES 10.25.2023 Mars Companion Fund to take bigger bets on petcare startups GLOBAL CORPORATE VENTURING > Native Pet 10.16.2023 Native Pet launches new all-in-one supplement Pet Food Processing > Faeth Therapeutics 10.13.2023 Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee Business Wire > Eden Brew 10.11.2023 Eden Brew alternative milk startup attracts $25m i … Wire > DIGITALIS VENTURES 10.3.2023 Mars and Digitalis Ventures launch $300m Fund to improve the lives of pets… MARS > Terray Therapeutics 10.2023 A New Molecular Language for Generative AI in Small-Molecule Drug Discovery NVIDIA > GRO Biosciences 9.27.2023 GRO Biosciences Presents Preclinical Data on Two ProGly™ Programs for Non-Standard Amino Acid Therapies Business Wire > PetMedix 9.19.2023 More animal magic as Zoetis acquires PetMedix in Cambridge Business Wee … ces 4.11.2023 GRO Biosciences CEO, Daniel J. Mandell, PhD, Awarded 2023 Termeer Fellowship Business Wire > Switch Therapeutics 3.14.2023 Switch Therapeutics Raises $52M in Series A Funding FINSMES > Code Ocean 2.17.2023 Code Ocean Partners with Nature Portfolio to Launch the Open Science Library with Ready-to-Run Software from Authors in Na
Metformin's Role in Healthy Longevity: Separating Fact from Theory | Andrea B. Maier posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.3 %���� 911 0 obj > endobj xref 911 63 0000000016 00000 n 0000001611 00000 n 0000006886 00000 n 0000007231 00000 n 0000007696 00000 n 0000008006 00000 n 0000010019 00000 n 0000010578 00000 n 0000011381 00000 n 0000011422 00000 n 0000011797 00000 n 0000012512 00000 n 0000012918 00000 n 0000013263 00000 n 0000013441 00000 n 0000014092 00000 n 0000014290 00000 n 0000014361 00000 n 0000014413 00000 n 0000014465 00000 n 0000014488 00000 n 0000016057 00000 n 0000016080 00000 n 0000017830 00000 n 0000017853 00000 n 0000019197 00000 n 0000019220 00000 n 0000020600 00000 n 0000020623 00000 n 000 … WCsfpGc3q/DyZZSjEUT3B6jSY548UYyNkB//Z uuid:dff0ac15-72db-11da-8e76-000d936d0d3c application/postscript endstream endobj 971 0 obj > endobj 1 0 obj > endobj 2 0 obj > /Font > /XObject > /ProcSet [ /PDF /Text /ImageC /ImageI ] /ExtGState > /Shading > /Properties > >> endobj 3 0 obj > stream H��WM� � ����crpY$�A]w�r v��}g�8s��ϣJ�R�ԛ�'���L� ��|���*�5{)�Km ��6�, �� ҂�Z����|H�R�2iHr��$[��2]�����4�2����,�r�X������:���E�.�s��dy��>��� ���=��VN[ͽ��U�{�{0[ȷ܁�W�}) �HM�sq� … q�8�I�*�0 %�m��D���#�����WX���T�����N�6���w�4� �!ѻ�c7M��M��*u+]� ����rfP��;����k]i�u���}�X�f��'cw��+�þ��Z��ڀtJsYV8HD K��[@�y)�r����+�a $�6�[�o���vI=K�� � �^��-��^;3�@�F�o�%��jw ᢷK�,����(�G ֩o�X�VK�(�4�kCZ��Nh=��T��� �)O���X�+�Q� ���1����d*�K�c�J1� c��&����T����qk��i>eQg�ܜ ������5�,���y+���Y�n�jٛF%;�1��>K ��P��j�� ��ۑi�����$��lڱ��d��2���H}{���� U�N4���� Ġd��> �?I�� �͵� � �L�nK+�k��G��}�uL����Q1��S=# �/H�� ������q�P�f�6�y쁋���l; … WCsfpGc3q/DyZZSjEUT3B6jSY548UYyNkB//Z uuid:dff0ac15-72db-11da-8e76-000d936d0d3c application/postscript endstream endobj 104 0 obj > endobj 105 0 obj > endobj 106 0 obj > /Font > /XObject > /ProcSet [ /PDF /Text /ImageC /ImageI ] /ExtGState > /Properties > >> endobj 107 0 obj > stream H��WɎ%� �����}��ܗ�$���� ��l�������;H&�Y�Ӡ��at��%�d}y��ۣ��žU�����T���GW��G�n�� ����������_��n���� ����_����� S٢�}��py��O�� ?��@g�{{|~{ ���~~�=o?�ۻ��`������=��"z�[�ߝ��:�භw���?��Ƿ=����"� … WCsfpGc3q/DyZZSjEUT3B6jSY548UYyNkB//Z uuid:dff0ac15-72db-11da-8e76-000d936d0d3c application/postscript endstream endobj 110 0 obj > endobj 111 0 obj > stream 2005-10-05T09:28:33Z 2005-10-24T18:33:57Z Illustrator JPEG 256 72 /9j/4AAQSkZJRgABAgEASABIAAD/7QAsUGhvdG9zaG9wIDMuMAA4QklNA+0AAAAAABAASAAAAAEA
AQBIAAAAAQAB/+4ADkFkb2JlAGTAAAAAAf/bAIQABgQ
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
in vitro and in vivo services in CNS & Neurology - BRAINXPLORE --> --> --> --> --> --> --> --> --> --> --> --> --> --> CRO Services Working with us Company Resources News Career Fr / En Contact us → Home CRO Services → Working with us Resources Company News Career Contact Fr / En ← Menu By Service Dermatology → Neurology & CNS → Cardiovascular → Neurovascular & Stroke → By service In Vitro Efficacy Study In Vivo Efficacy Study Analytical services Non-Regulatory Safety PK/PD Scientific consulting By technology High Content Imaging Brain-on-Chip Small &
Patrizia D'Alessio, Founder of AISA Care | Research Our Products All our products Explore our anti-inflammatory & wellness solutions Discover Anti-inflammatory capsules AISA Moleculum 120€ Best seller AISA routine Discover the routine to implement Top Action Science Science & Evidence Silent inflammation Stress & cortisol Gut, brain & skin axis Senescence & inflammaging D-Limonene Advice Approach Founder AISA Vision Research & Innovation Partners Help Support & FAQ Delivery Returns & Refunds Contact EN FR 0 AISA moleculum Founder The history of AISA Care Wh … was founded Chapter III The birth of AISA Care In 2005, armed with the National Prize for Innovative Business Creation awarded by the Ministry of Research, Patrizia D'Alessio took a step that few researchers dare to take: she founded AISA Therapeutics, still remaining at University until the end of the RISTOMED trial. The name says it all: Anti-Inflammatory Senescence Actives . Not just another cosmetics brand. An applied science approach, rooted in years of fundamental … sm of aging. And it can be changed. 2005 Founding of AISA Therapeutics National Award for Innovative Business Creation by the Ministry of Research 2005 3 International Patents Filed simultaneously in Europe, the United States, and China 2013 RISTOMED clinical validation European FP7 consortium: first human evidence of the anti-inflammatory efficacy of d- Limonene 2015 Launch of AISA moleculum® First nutraceutical product derived from fundamental research made available to the
SRF would like to take a... - Lifespan Research Institute Facebook Log In Lifespan Research Institute's Post Lifespan Research Institute October 19, 2023 · Shared with Public SRF would like to take a second to appreciate our incredible team! Meet Staff Scientist I, Dr. Marcela Atzori. "I was born and used to live in a small town southeast from Mexico City called San Rafael. I shared my childhood with the two most important people who shaped my life: my grandmother and my great-grandmother. Both of them were old enough to share with me every day their wisdom, serenity, kindness, and j
Africa's quest for healthy longevity Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search TrimTech adds $14m in fundi... Winona study finds 3 … e menopause symptoms simultaneously GARM Clinic launches first Klotho longevity residency in Roatan Cognito’s wearable device boosts brain proteins linked to Alzheimer’s protection Lys Therapeutics raises over $27m to advance new treatments for Parkinson’s and stroke RELATED ARTICLES An EU moonshot to solve aging Insurance confronts the longevity challenge Your DNA may know your future – now it costs just $599 to find out You might also like An EU moonshot t
%PDF-1.4 %���� 1596 0 obj > endobj xref 1596 84 0000000016 00000 n 0000011461 00000 n 0000011586 00000 n 0000011965 00000 n 0000012289 00000 n 0000013082 00000 n 0000013197 00000 n 0000013858 00000 n 0000014481 00000 n 0000014566 00000 n 0000014992 00000 n 0000015355 00000 n 0000017182 00000 n 0000018380 00000 n 0000018874 00000 n 0000018952 00000 n 0000018993 00000 n 0000056666 00000 n 0000056862 00000 n 0000057013 00000 n 0000057336 00000 n 0000057724 00000 n 0000057916 00000 n 0000058041 00000 n 0000058429 00000 n 0000058620 00000 n 0000058745 00000 n 0000059133 00000 n 0000059328 00000 n 0 … Z(�NX6�t! 8� ��Q����)�fÝe(���� > endobj 1611 0 obj > endobj 1612 0 obj >stream application/pdf colors1 2015-05-18T11:04:02+02:00 2015-05-18T11:04:02+02:00 2014-12-05T17:37:33-04:00 Adobe Illustrator CC 2014 (Windows) uuid:74afdbe3-698b-8c43-8473-79e40fb73ca3 xmp.did:620bbf1d-20a8-fd41-9ab2-92281d1d0888 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:edddafb5-d0c5-465b-bd52-2234cadc29b1 xmp.did:c9db2d6b-0b1a-7544-a9f0-e13795bbc653 uuid:5D20892493BFDB11914A8590D31508C8 pr … ' �jқYd�N�c�����_�מT��[ ��X$fmå�}�����5N�jH�O�W5�NRU�B�{� �* >stream application/pdf colors1 2015-05-18T11:04:02+02:00 2015-05-18T11:04:02+02:00 2014-12-05T17:37:33-04:00 Adobe Illustrator CC 2014 (Windows) uuid:74afdbe3-698b-8c43-8473-79e40fb73ca3 xmp.did:620bbf1d-20a8-fd41-9ab2-92281d1d0888 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:edddafb5-d0c5-465b-bd52-2234cadc29b1 xmp.did:c9db2d6b-0b1a-7544-a9f0-e13795bbc653 uuid:5D20892493BFDB11914A8590D31508C8 pr … ��.�ޮ]��� �x�d��rR��2�����~�Y�Ȧ\�5�� B��. endstream endobj 94 0 obj >stream application/pdf colors1 2015-05-18T11:04:02+02:00 2015-05-18T11:04:02+02:00 2014-12-05T17:37:33-04:00 Adobe Illustrator CC 2014 (Windows) uuid:74afdbe3-698b-8c43-8473-79e40fb73ca3 xmp.did:620bbf1d-20a8-fd41-9ab2-92281d1d0888 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:edddafb5-d0c5-465b-bd52-2234cadc29b1 xmp.did:c9db2d6b-0b1a-7544-a9f0-e13795bbc653 uuid:5D20892493BFDB11914A8590D31508C8 pr … њ�#�M��� n;K.���Il�uY���j_$00 բJ�� �����bpk5݄ـ�t�t�+������ij�n� ,� >stream application/pdf colors1 2015-05-18T11:04:02+02:00 2015-05-18T11:04:02+02:00 2014-12-05T17:37:33-04:00 Adobe Illustrator CC 2014 (Windows) uuid:74afdbe3-698b-8c43-8473-79e40fb73ca3 xmp.did:620bbf1d-20a8-fd41-9ab2-92281d1d0888 uuid:5D20892493BFDB11914A8590D31508C8 proof
#longevity | Alex Zhavoronkov LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Sk
#aisatherapeutics #senescence #inflammatory #antiinflammatory #science #aging #antiaging | AISA Therapeutics - Anti-Inflammatory Senescence Actives LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By
Oxford Properties, Novaxia’s French Life Science JV Buys its First Asset Skip to main content Search This Blog Pension Pulse Daily Insights on Pensions and Financial Markets Oxford Properties, Novaxia’s French Life Science JV Buys its First Asset Get link Facebook X Pinterest Email Other Apps By Leo Kolivakis November 17, 2022 IPE Real Assets reports Oxford Properties, Novaxia’s French life science JV buys first asset: A newly partnership between Oxford Properties and French urban developer Novaxia has acquired a 21,000sqft life sciences campus in Paris as its first asset. Th … ion Plan (OTPP) stands to reap one of the most extraordinary returns in pension fund history thanks to a bold 2019 investment in SpaceX. According to a recent report from The Globe and Mail , the Toronto-based fund invested roughly $300 million CAD (~$220 million USD at the time) in Elon Musk’s space company as its inaugural deal through the Teachers’ Innovation Platform. At SpaceX’s anticipated $1.75 trillion IPO valuation, set for a mid-June debut on Nasda … turn and easily become OTPP’s most successful single investment ever. The fund manages $279 billion in assets for approximately 346,000 working and retired teachers in Ontario, potentially delivering an average boost of around $33,500 pe... Read more BCI Shuts Two Internal Stock Funds By Leo Kolivakis May 27, 2026 Layan Odeh of Bloomberg reports BCI shuts two stock funds, cites shrinking public pool: British Columbia Investment Management Corp. is closing two global sto … ), as it contends with a contracting pool of publicly listed firms. The pension fund manager is retiring two internally managed global strategies focused on thematic and fundamental equities, BCI said an emailed statement to Bloomberg. The strategies, Global Active Thematic Equities and Global Active Fundamental Equities, make up about 7.2% of its public equities portfolio. “The opportunity set for active fundamental stock selection in global developed equities has redu … rise of passive investing has fur... Read more Norway's Giant Sovereign Wealth Fund to Stay the Course With US Exposure By Leo Kolivakis April 15, 2026 Chris Wellisz of Semafor World Economy reports  Norway will keep $1 trillion in US stocks, finance minister says:  Norway’s $2.1 trillion sovereign wealth fund, the world’s
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.